Details for Patent: 7,612,109
✉ Email this page to a colleague
Which drugs does patent 7,612,109 protect, and when does it expire?
Patent 7,612,109 protects INJECTAFER and is included in one NDA.
This patent has fifty patent family members in twenty-nine countries.
Summary for Patent: 7,612,109
| Title: | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
| Abstract: | Water soluble iron carbohydrate complex obtainable from an aqueous solution of iron (III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and medicament for the treatment and prophylaxis of iron deficiency conditions. |
| Inventor(s): | Geisser; Peter (St. Gallen, CH), Philipp; Erik (Wittenbach, CH), Richle; Walter (Gossau, CH) |
| Assignee: | Vifor (International) AG (St. Gallen, CH) |
| Application Number: | 10/531,895 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,612,109 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; Process; |
Drugs Protected by US Patent 7,612,109
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-003 | Apr 28, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-001 | Jul 25, 2013 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-004 | Feb 4, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-002 | Oct 8, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,612,109
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Germany | 102 49 552 | Oct 23, 2002 |
| PCT Information | |||
| PCT Filed | October 20, 2003 | PCT Application Number: | PCT/EP03/11596 |
| PCT Publication Date: | May 06, 2004 | PCT Publication Number: | WO2004/037865 |
International Family Members for US Patent 7,612,109
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 041472 | ⤷ Try a Trial | |||
| Austria | 507246 | ⤷ Try a Trial | |||
| Australia | 2003278111 | ⤷ Try a Trial | |||
| Brazil | 0315452 | ⤷ Try a Trial | |||
| Brazil | PI0315452 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
